Measuring Revenue Streams and Profitability for HIV Drugs

Abstract

In this report, we estimate revenue streams and profitability for HIV drug treatments. In particular, we compile information regarding HIV disease prevalence and incidence rates, antiretroviral therapy (ART) coverage, future population growth, and drug prices. This material allows us to estimate the revenue streams available to drug-makers. Our research focuses on the six most populous sub-Saharan and North African nations (Democratic Republic of Congo, Egypt, Ethiopia, Nigeria, South Africa, and Tanzania) as well as potential returns for investment in Africa, the Middle East, and the world as a whole. This paper is the latest in a series of publications under the Brookings Private Sector Global Health R&D Project. Past reports examined health governance capacity, private funding levels, rate of return on investment, and barriers to private investment.